{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:46:45Z","timestamp":1772135205549,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["80018019238"],"award-info":[{"award-number":["80018019238"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["ZW7-8515131"],"award-info":[{"award-number":["ZW7-8515131"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["ZW7-85151373"],"award-info":[{"award-number":["ZW7-85151373"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"EC | European Regional Development Fund","doi-asserted-by":"publisher","award":["ZW7-8515131"],"award-info":[{"award-number":["ZW7-8515131"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Heterologous prime\/boost vaccination with a vector-based approach (ChAdOx-1nCov-19, ChAd) followed by an mRNA vaccine (e.g. BNT162b2, BNT) has been reported to be superior in inducing protective immunity compared to repeated application of the same vaccine. However, data comparing immunity decline after homologous and heterologous vaccination as well as effects of a third vaccine application after heterologous ChAd\/BNT vaccination are lacking. Here we show longitudinal monitoring of ChAd\/ChAd (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200941) and ChAd\/BNT (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200988) vaccinated individuals and the impact of a third vaccination with BNT. The third vaccination greatly augments waning anti-spike IgG but results in only moderate increase in spike-specific CD4\u2009+\u2009and CD8\u2009+\u2009T cell numbers in both groups, compared to cell frequencies already present after the second vaccination in the ChAd\/BNT group. More importantly, the third vaccination efficiently restores neutralizing antibody responses against the Alpha, Beta, Gamma, and Delta variants of the virus, but neutralizing activity against the B.1.1.529 (Omicron) variant remains severely impaired. In summary, inferior SARS-CoV-2 specific immune responses following homologous ChAd\/ChAd vaccination can be compensated by heterologous BNT vaccination, which might influence the choice of vaccine type for subsequent vaccination boosts.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-32527-2","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T15:02:52Z","timestamp":1660834972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["BNT162b2-boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19\/BNT162b2 vaccination against COVID-19"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3111-621X","authenticated-orcid":false,"given":"Georg M. N.","family":"Behrens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3370-4990","authenticated-orcid":false,"given":"Joana","family":"Barros-Martins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Cossmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4835-5172","authenticated-orcid":false,"given":"Gema Morillas","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Metodi V.","family":"Stankov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Odak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7129-100X","authenticated-orcid":false,"given":"Alexandra","family":"Dopfer-Jablonka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Hetzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miriam","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwendolyn","family":"Patzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6789-4967","authenticated-orcid":false,"given":"Christoph","family":"Binz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Friedrichsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3307-2639","authenticated-orcid":false,"given":"Christian","family":"Schultze-Florey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inga","family":"Ravens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Willenzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Bubke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasmin","family":"Ristenpart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anika","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5350-3371","authenticated-orcid":false,"given":"George","family":"Ssebyatika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Kr\u00e4hling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0510-2853","authenticated-orcid":false,"given":"G\u00fcnter","family":"Bernhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4603-7696","authenticated-orcid":false,"given":"Markus","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"P\u00f6hlmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4548-7241","authenticated-orcid":false,"given":"Thomas","family":"Krey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3374-7488","authenticated-orcid":false,"given":"Berislav","family":"Bo\u0161njak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0718-0422","authenticated-orcid":false,"given":"Swantje I.","family":"Hammerschmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6190-7923","authenticated-orcid":false,"given":"Reinhold","family":"F\u00f6rster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"32527_CR1","doi-asserted-by":"crossref","unstructured":"Powell, A. A. et al. Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March-June 2021, England. Euro Surveill. 26, 2100634 (2021).","DOI":"10.2807\/1560-7917.ES.2021.26.28.2100634"},{"key":"32527_CR2","doi-asserted-by":"publisher","first-page":"eabn8057","DOI":"10.1126\/scitranslmed.abn8057","volume":"14","author":"JP Evans","year":"2022","unstructured":"Evans, J. P. et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci. Transl. Med. 14, eabn8057 (2022).","journal-title":"Sci. Transl. Med."},{"key":"32527_CR3","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/S2213-2600(21)00456-2","volume":"9","author":"P Tober-Lau","year":"2021","unstructured":"Tober-Lau, P. et al. Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. Lancet Respir. Med. 9, e104\u2013e105 (2021).","journal-title":"Lancet Respir. Med."},{"key":"32527_CR4","doi-asserted-by":"crossref","unstructured":"Arbel, R. et al. BNT162b2 Vaccine Booster and Mortality Due to Covid-19. N. Engl. J. Med. 385, 2413\u20132420 (2021).","DOI":"10.1056\/NEJMoa2115624"},{"key":"32527_CR5","doi-asserted-by":"crossref","unstructured":"Hansen, C. H. et al. Institut TIDPGaSS. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: a Danish cohort study. medRxiv. 2021:2021.12.20.21267966.","DOI":"10.1101\/2021.12.20.21267966"},{"key":"32527_CR6","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1056\/NEJMoa2115926","volume":"385","author":"YM Bar-On","year":"2021","unstructured":"Bar-On, Y. M. et al. Protection against Covid-19 by BNT162b2 booster across age groups. N. Engl. J. Med 385, 2421\u201330. (2021).","journal-title":"N. Engl. J. Med"},{"key":"32527_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41586-022-04411-y","volume":"603","author":"R Viana","year":"2022","unstructured":"Viana, R. et al. Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in Southern Africa. Nature 603, 679\u2013686. (2022).","journal-title":"Nature"},{"key":"32527_CR8","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2021.12.032","volume":"185","author":"M Hoffmann","year":"2022","unstructured":"Hoffmann, M. et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell 185, 447\u2013456 e11 (2022).","journal-title":"Cell"},{"key":"32527_CR9","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMc2119641","volume":"386","author":"F Schmidt","year":"2022","unstructured":"Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N. Engl. J. Med 386, 599\u2013601 (2022).","journal-title":"N. Engl. J. Med"},{"key":"32527_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-021-01676-0","volume":"28","author":"H Gruell","year":"2022","unstructured":"Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med 28, 477\u2013480. (2022).","journal-title":"Nat. Med"},{"key":"32527_CR11","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","volume":"9","author":"D Hillus","year":"2021","unstructured":"Hillus, D. et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir. Med 9, 1255\u20131265. (2021).","journal-title":"Lancet Respir. Med"},{"key":"32527_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(21)01699-8","volume":"398","author":"A Flaxman","year":"2021","unstructured":"Flaxman, A. et al. Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). Lancet 398, 981\u2013990. (2021).","journal-title":"Lancet"},{"key":"32527_CR13","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy, M. N. et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet 396, 1979\u20131993. (2021).","journal-title":"Lancet"},{"key":"32527_CR14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","volume":"398","author":"AM Borobia","year":"2021","unstructured":"Borobia, A. M. et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet 398, 121\u2013130. (2021).","journal-title":"Lancet"},{"key":"32527_CR15","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","volume":"27","author":"J Barros-Martins","year":"2021","unstructured":"Barros-Martins, J. et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination. Nat. Med 27, 1525\u20131529 (2021).","journal-title":"Nat. Med"},{"key":"32527_CR16","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41591-021-01464-w","volume":"27","author":"T Schmidt","year":"2021","unstructured":"Schmidt, T. et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19\/mRNA vaccination. Nat. Med 27, 1530\u20131535 (2021).","journal-title":"Nat. Med"},{"key":"32527_CR17","doi-asserted-by":"crossref","unstructured":"Pozzetto, B. et al. Immunogenicity and efficacy of heterologous ChAdOx1-BNT162b2 vaccination. Nature 600, 701\u2013706 (2021).","DOI":"10.1038\/s41586-021-04120-y"},{"key":"32527_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41423-020-00573-9","volume":"18","author":"B Bosnjak","year":"2021","unstructured":"Bosnjak, B. et al. Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods. Cell Mol. Immunol. 18, 936\u201344. (2021).","journal-title":"Cell Mol. Immunol."},{"key":"32527_CR19","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1038\/s41423-021-00755-z","volume":"18","author":"SI Hammerschmidt","year":"2021","unstructured":"Hammerschmidt, S. I. et al. Neutralization of the SARS-CoV-2 Delta variant after heterologous and homologous BNT162b2 or ChAdOx1 nCoV-19 vaccination. Cell Mol. Immunol. 18, 2455\u20132456 (2021).","journal-title":"Cell Mol. Immunol."},{"key":"32527_CR20","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","volume":"184","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384\u20132393 e12 (2021).","journal-title":"Cell"},{"key":"32527_CR21","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41591-022-01715-4","volume":"28","author":"PR Wratil","year":"2022","unstructured":"Wratil, P. R. et al. Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern. Nat. Med 28, 496\u2013503 (2022).","journal-title":"Nat. Med"},{"key":"32527_CR22","doi-asserted-by":"publisher","first-page":"e1003991","DOI":"10.1371\/journal.pmed.1003991","volume":"19","author":"MJ van Gils","year":"2022","unstructured":"van Gils, M. J. et al. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Med 19, e1003991 (2022).","journal-title":"PLoS Med"},{"key":"32527_CR23","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.jinf.2022.02.026","volume":"84","author":"JY Hayashi","year":"2022","unstructured":"Hayashi, J. Y. et al. Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2. J. Infect. 84, 834\u2013872. (2022).","journal-title":"J. Infect."},{"key":"32527_CR24","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","volume":"398","author":"APS Munro","year":"2021","unstructured":"Munro, A. P. S. et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet 398, 2258\u20132276. (2021).","journal-title":"Lancet"},{"key":"32527_CR25","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/s41586-021-04386-2","volume":"602","author":"E Cameroni","year":"2022","unstructured":"Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664\u2013670. (2022).","journal-title":"Nature"},{"key":"32527_CR26","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41586-021-04389-z","volume":"602","author":"D Planas","year":"2022","unstructured":"Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671\u2013675 (2022).","journal-title":"Nature"},{"key":"32527_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1056\/NEJMc2119358","volume":"386","author":"I Nemet","year":"2022","unstructured":"Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection. N. Engl. J. Med 386, 492\u2013494 (2022).","journal-title":"N. Engl. J. Med"},{"key":"32527_CR28","doi-asserted-by":"publisher","unstructured":"Wilhelm, A. et al. Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies. medRxiv. (2021) https:\/\/doi.org\/10.1101\/2021.12.07.21267432.","DOI":"10.1101\/2021.12.07.21267432"},{"key":"32527_CR29","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.cell.2021.12.046","volume":"185","author":"W Dejnirattisai","year":"2022","unstructured":"Dejnirattisai, W. et al. SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. Cell 185, 467\u2013484 e15 (2022).","journal-title":"Cell"},{"key":"32527_CR30","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","volume":"602","author":"L Liu","year":"2022","unstructured":"Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676\u2013681. (2022).","journal-title":"Nature"},{"key":"32527_CR31","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/S0140-6736(22)00092-7","volume":"399","author":"M Wu","year":"2022","unstructured":"Wu, M. et al. Three-dose vaccination elicits neutralising antibodies against omicron. Lancet 399, 715\u2013717 (2022).","journal-title":"Lancet"},{"key":"32527_CR32","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(22)00277-X","volume":"399","author":"H Chemaitelly","year":"2022","unstructured":"Chemaitelly, H. & Abu-Raddad, L. J. Waning effectiveness of COVID-19 vaccines. Lancet 399, 771\u2013773 (2022).","journal-title":"Lancet"},{"key":"32527_CR33","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJMoa2115481","volume":"386","author":"N Andrews","year":"2022","unstructured":"Andrews, N. et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N. Engl. J. Med 386, 340\u2013350. (2022).","journal-title":"N. Engl. J. Med"},{"key":"32527_CR34","doi-asserted-by":"publisher","first-page":"255","DOI":"10.15585\/mmwr.mm7107e2","volume":"71","author":"JM Ferdinands","year":"2022","unstructured":"Ferdinands, J. M. et al. Waning 2-Dose and 3-Dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of delta and omicron variant predominance - VISION network, 10 states, August 2021-January 2022. MMWR Morb. Mortal. Wkly Rep. 71, 255\u2013263 (2022).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"32527_CR35","doi-asserted-by":"crossref","unstructured":"Bar-On, Y. M. et al Protection by a fourth dose of BNT162b2 against Omicron in Israel. N. Engl. J. Med. 386, 1712\u20131720 (2022).","DOI":"10.1056\/NEJMoa2201570"},{"key":"32527_CR36","doi-asserted-by":"crossref","unstructured":"Ying, B. et al. Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell 185, 1572\u20131587 (2022).","DOI":"10.1016\/j.cell.2022.03.037"},{"key":"32527_CR37","doi-asserted-by":"crossref","unstructured":"Gagne, M. et al. mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron. Cell 185, 1556\u20131571 (2022).","DOI":"10.1016\/j.cell.2022.03.038"},{"key":"32527_CR38","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","volume":"398","author":"X Liu","year":"2021","unstructured":"Liu, X. et al. Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. Lancet 398, 856\u2013869. (2021).","journal-title":"Lancet"},{"key":"32527_CR39","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1038\/s41591-022-01700-x","volume":"28","author":"Y Gao","year":"2022","unstructured":"Gao, Y. et al. Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant. Nat. Med 28, 472\u2013476 (2022).","journal-title":"Nat. Med"},{"key":"32527_CR40","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2022.01.015","volume":"185","author":"A Tarke","year":"2022","unstructured":"Tarke, A. et al. SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron. Cell 185, 847\u2013859 e11 (2022).","journal-title":"Cell"},{"key":"32527_CR41","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41586-022-04460-3","volume":"603","author":"R Keeton","year":"2022","unstructured":"Keeton, R. et al. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Nature 603, 488\u2013492. (2022).","journal-title":"Nature"},{"key":"32527_CR42","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1001\/jamaneurol.2022.0245","volume":"79","author":"N Madelon","year":"2022","unstructured":"Madelon, N. et al. Omicron-Specific Cytotoxic T-Cell Responses After a Third Dose of mRNA COVID-19 Vaccine Among Patients With Multiple Sclerosis Treated With Ocrelizumab. JAMA Neurol. 79, 399\u2013404 (2022).","journal-title":"JAMA Neurol."},{"key":"32527_CR43","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s15010-020-01461-0","volume":"48","author":"GMN Behrens","year":"2020","unstructured":"Behrens, G. M. N. et al. Perceived versus proven SARS-CoV-2-specific immune responses in health-care professionals. Infection 48, 631\u2013634 (2020).","journal-title":"Infection"},{"key":"32527_CR44","doi-asserted-by":"crossref","unstructured":"Jablonka, A. et al. Protocol for longitudinal assessment of SARS-CoV-2-specific immune responses in healthcare professionals in Hannover, Germany: the prospective, longitudinal, observational COVID-19 Contact (CoCo) study. medRxiv. (2020) 10.1101\/2020.12.02.20242479.","DOI":"10.1101\/2020.12.02.20242479"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32527-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32527-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32527-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:36:37Z","timestamp":1669296997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-32527-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["32527"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-32527-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1200506\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.1101\/2021.12.25.21268392","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]},"assertion":[{"value":"24 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4872"}}